Key Points
Jason M. Hollar disposed of 125,000 shares at a weighted average price of $235.89 per share across two trading sessions.
The divestment involved only directly held shares; Hollar retains nearly 191,000 shares valued at $44.76 million following the sale.
The liquidity event occurred following a 58% one-year return for the stock as of the August 19 market close.
Chief Executive Officer Jason M. Hollar sold nearly 125,000 shares of Cardinal Health, Inc. (NYSE:CAH) for $29.4 million on August 18 and August 19, according to an SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold | 124,529 |
| Transaction value | ~$29.4 million |
| Post-transaction shares (directly held) | 190,603 |
| Post-transaction value | ~$44.76 million |
Transaction value based on SEC Form 4 weighted average sale price ($235.89); post-transaction value based on the August 19 market close ($234.85).
Key questions
- What is the current equity stake of the Chief Executive Officer following this sale?
Hollar retains 190,603 shares held directly, representing a 0.0814% ownership interest in the $55.0 billion company. - What pricing ranges were utilized for this $29.4 million disposition?
According to the SEC filing footnotes, the shares were sold in multiple tranches with execution prices ranging from $232.75 to $238.07 per share. - What are the primary operational segments of Cardinal Health?
The company functions as a global integrated healthcare services provider organized into two core divisions, Pharmaceutical and Medical, serving hospitals, pharmacies, and physician practices. - What is the scale of the company's recent financial performance?
Cardinal Health reported trailing twelve-month revenue of $254.2 billion and net income of $1.7 billion, reflecting its position as a major distributor in the healthcare sector.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-19) | $234.85 |
| Market Capitalization | $55.0 billion |
| Revenue (TTM) | $254.2 billion |
| Net Income (TTM) | $1.7 billion |
Company Snapshot
- Cardinal Health operates as a global, integrated healthcare services and products provider, delivering pharmaceutical distribution, medical-surgical products, and healthcare solutions across the United States, Canada, Europe, Asia, and international markets.
- The company generates revenue through its two core operating divisions--Pharmaceutical and Medical--which provide distribution, sourcing, and specialty services to healthcare providers, with a business model centered on supply chain optimization and value-added services.
- Cardinal Health serves a diverse customer base, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical laboratories, physician practices, and patients receiving home care services.
Cardinal Health is one of the largest healthcare services and products companies globally, with a presence spanning multiple continents and serving over 58,700 employees. The company maintains a competitive advantage through its extensive distribution infrastructure, integrated service offerings, and deep relationships with healthcare providers across multiple care settings. With TTM revenue of $254.2 billion and a market capitalization of $55.0 billion, Cardinal Health represents a critical intermediary in the global healthcare supply chain.
What this transaction means for investors
Hollar has done this before: He sold 124,529 shares on Aug. 18 and 19, almost exactly the block that vested three days earlier from restricted stock and performance units, and last August he cleared about $16 million days after the same vest. Despite the $29.4 million headline, his directly held stake sits about where it did a year ago.
Meanwhile, he's selling into a stock that has run hard. Cardinal closed fiscal 2026 with revenue up 14% to $254 billion and $5 billion in adjusted free cash flow, and on Aug. 11 the board tacked another $5 billion onto the buyback authorization. Non-GAAP earnings per share have more than doubled since fiscal 2022, to $11.26 from $5.07, the stretch Hollar had in mind when he told analysts earlier this month the company is "in a very different place."
The soft spot, however, is medical products and distribution, where fiscal 2027 guidance assumes tariff relief cancels out rising diesel and resin costs. CFO Aaron Alt said a drawn-out Iran conflict would push that segment to the bottom of its $200 million to $220 million profit range, and management has already told investors to model first-quarter profit there at about half of last year's.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.